{
    "clinical_study": {
        "@rank": "13471", 
        "arm_group": [
            {
                "arm_group_label": "Insulin treated", 
                "description": "Newly started on insulin for hyperglycaemia"
            }, 
            {
                "arm_group_label": "Dipeptidyl peptidase 4 inhibitor (DPP4) treated", 
                "description": "Newly started on DPP4 inhibitor for hyperglycaemia"
            }, 
            {
                "arm_group_label": "Glucagon like peptide 1 (GLP-1) treated", 
                "description": "Newly started on GLP-1 for hyperglycaemia or obesity"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to determine if different diabetes treatments have different effects on\n      inflammation; in particular, kidney inflammation. This type of inflammation is common in\n      people with diabetes, and can lead to kidney failure. This study will investigate the effect\n      of different types of diabetes treatment on kidney inflammation. This will help us to decide\n      if certain types of medicine should be preferred in people with evidence of inflammation in\n      their kidneys, as this may help prevent major complications including kidney failure."
        }, 
        "brief_title": "The Differential Effects of Diabetes Therapy on Inflammation", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetic Nephropathy", 
            "Type 2 Diabetes"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Diabetic Nephropathies", 
                "Inflammation", 
                "Kidney Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age over 30 years\n\n          -  Diagnosis of type 2 diabetes for one year or more\n\n          -  Diagnosis of DKD as defined by two distinct albumin:creatinine ratio measurements\n             above the gender specific range in the local reference laboratory with an interval of\n             no less than eight week between measurements\n\n          -  Stable dose of an inhibitor of the renin angiotensin system for a period of 8 weeks\n\n        Exclusion Criteria:\n\n          -  Any cognitive impediment that preclude the participant from giving free and informed\n             consent\n\n          -  Substance abuse including alcohol excess\n\n          -  Use of a GLP-1 analogue in the last 6 months\n\n          -  Pregnancy\n\n          -  Hypersensitivity to the prescribed treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "This study will be a prospective cohort study with 120 participants: 40 per group. I have\n        calculated this sample size to achieve a 90% power based on a 50% reduction in urinary\n        chemokines and circulating pro-inflammatory immune cells 1-4. This power calculation\n        anticipates a 10% dropout rate.\n\n        Patients with DKD presenting to the diabetes service of St Vincent's University Hospital\n        (SVUH) and Mater Misericordiae University Hospital (MMUH) who are commenced on GLP-1,\n        DPP4i or insulin for the first time will be invited to participate in the study."
            }
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02150707", 
            "org_study_id": "DPP4201401"
        }, 
        "intervention": [
            {
                "arm_group_label": "Insulin treated", 
                "intervention_name": "Insulin, Long-Acting", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Insulin glargine", 
                    "Insulin detemir", 
                    "Mixed/biphasic insulin", 
                    "Insulin lispro", 
                    "Insulin aspart", 
                    "Insulin glulisine"
                ]
            }, 
            {
                "arm_group_label": "Dipeptidyl peptidase 4 inhibitor (DPP4) treated", 
                "intervention_name": "Dipeptidyl-Peptidase IV Inhibitors", 
                "intervention_type": "Drug", 
                "other_name": "DPP4 inhibitors"
            }, 
            {
                "arm_group_label": "Glucagon like peptide 1 (GLP-1) treated", 
                "intervention_name": "Glucagon-Like Peptide 1", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Liraglutide", 
                    "Exenatide"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glucagon", 
                "Glucagon-Like Peptide 1", 
                "Insulin aspart", 
                "Insulin LISPRO", 
                "Glargine", 
                "Insulin glulisine", 
                "Insulin", 
                "Insulin, Long-Acting", 
                "Dipeptidyl-Peptidase IV Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "contact": {
                "last_name": "Mensud Hatunic, MD MRCPI"
            }, 
            "facility": {
                "address": {
                    "city": "Dublin", 
                    "country": "Ireland", 
                    "zip": "Dublin 7"
                }, 
                "name": "Mater Misericordiae University Hospital"
            }, 
            "investigator": {
                "last_name": "Karl J Neff, MB MRCPI", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Ireland"
        }, 
        "number_of_groups": "3", 
        "official_title": "The Differential Effects of Diabetes Therapy on Inflammation", 
        "overall_contact": {
            "email": "karl.neff@ucd.ie", 
            "last_name": "Karl J Neff, MB MRCPI", 
            "phone": "0035317166606", 
            "phone_ext": "6606"
        }, 
        "overall_official": [
            {
                "affiliation": "University College Dublin", 
                "last_name": "Donal O'Shea, MD FRCPI", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "University College Dublin", 
                "last_name": "Carel W le Roux, PhD MB FRCP", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "University College Dublin", 
                "last_name": "Mensud Hatunic, MD MRCPI", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ireland: Medical Council of Ireland", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Monocyte:chemoattractant protein 1 (MCP-1):creatinine ratio", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "reference": [
            {
                "PMID": "22608055", 
                "citation": "Fenske WK, Dubb S, Bueter M, Seyfried F, Patel K, Tam FW, Frankel AH, le Roux CW. Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. Surg Obes Relat Dis. 2013 Jul-Aug;9(4):559-68. doi: 10.1016/j.soard.2012.03.009. Epub 2012 Apr 10."
            }, 
            {
                "PMID": "24362727", 
                "citation": "Hogan AE, Gaoatswe G, Lynch L, Corrigan MA, Woods C, O'Connell J, O'Shea D. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia. 2014 Apr;57(4):781-4. doi: 10.1007/s00125-013-3145-0. Epub 2013 Dec 21. PubMed"
            }, 
            {
                "PMID": "21206136", 
                "citation": "Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2011;58(1):69-73. Epub 2010 Dec 28."
            }, 
            {
                "PMID": "21284481", 
                "citation": "Wu JD, Xu XH, Zhu J, Ding B, Du TX, Gao G, Mao XM, Ye L, Lee KO, Ma JH. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011 Feb;13(2):143-8. doi: 10.1089/dia.2010.0048. PubMed"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02150707"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University College Dublin", 
            "investigator_full_name": "Karl Neff", 
            "investigator_title": "Clinical Research Fellow", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Albumin:creatinine ratio", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "University College Dublin", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Irish Endocrine Society", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Royal College of Physicians", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Merck Sharp & Dohme Corp.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Eli Lilly and Company", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "University College Dublin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}